Baird cuts Ultragenyx Pharma to Neutral, trims price target
Baird downgraded Ultragenyx Pharma to Neutral and cut its price target to $16.00 per share from $40.00, according to ratings actions reported by Benzinga.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.